FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2017-03-03
Target enrollment:
Participant gender:
Summary
The goal of the Phase I part of this clinical research study is to find the highest tolerable
dose of a combination of dasatinib, cetuximab, and FOLFOX (5-fluorouracil [5-FU], leucovorin
[LV], and Eloxatin [oxaliplatin]) that can be given to patients with metastatic colorectal
cancer. The safety of these drugs in combination will also be studied.
The goal of the Phase II part of this clinical research study is to learn if dasatinib given
in combination with FOLFOX with or without cetuximab can help to control metastatic
colorectal cancer.